Metabolomics Workbench : NIH Data Repository

Clustering data with hclust algorithm for Lipidomics pilot project for mice exposure to bisphenol A and high fat diets (Study ST000779)

C18 NEGATIVE ION MODE (Analysis AN001232)

Metabolite	Structure	F1	F2	F3	F4	F5	F6	F7
PI 40:5; [M-H]-@5.02	ME216086	1.01	1.08	1.02	0.90	0.75	1.08	1.13
CL 78:7; [M-2H](2-)@5.85	ME215972	1.07	1.09	0.90	0.75	1.04	1.08	1.11
CL 70:3; [M-2H](2-)@5.63	ME215953	1.14	0.98	0.99	0.93	1.00	0.80	1.04
CL 80:3; [M-2H](2-)@6.89	ME215975	0.91	1.07	0.98	1.06	1.06	1.03	0.99
PE 33:2; [M-H]-@6.05	ME216025	0.94	1.02	0.99	1.11	0.90	1.09	1.01
PS 40:8; [M-H]-@4.90	ME216089	0.92	1.05	1.00	1.08	0.92	1.11	0.99
plasmenyl-PE 42:4; [M-H]-@8.11	ME216116	1.01	0.83	1.01	1.00	1.03	1.07	1.04
PA 34:0; [M-H]-@7.02	ME215981	0.99	0.93	1.00	1.01	1.04	0.99	1.05
PE 40:4; [M-H]-@7.37	ME216057	0.95	0.94	1.01	1.09	1.00	1.02	1.03
PG 36:0; [M-H]-@6.87	ME216070	1.08	1.06	0.88	1.02	1.02	0.96	1.02
lysoPE 22:4; [M-H]-@1.79	ME216097	1.04	1.06	0.96	0.91	0.92	1.01	1.08
PE 34:3; [M-H]-@5.96	ME216031	1.05	1.09	0.93	0.98	0.94	0.99	1.02
CL 80:13; [M-2H](2-)@6.05	ME215974	1.05	1.13	0.90	0.92	0.99	1.05	1.02
CL 70:5; [M-2H](2-)@6.00	ME215954	1.05	1.09	0.92	0.92	0.98	1.02	1.03
PE 42:9; [M-H]-@6.22	ME216064	1.06	1.06	0.92	0.93	0.95	1.05	1.04
CL 68:4; [M-2H](2-)@6.71	ME215952	1.08	1.09	0.92	0.86	1.08	0.97	0.99
CL 74:9; [M-2H](2-)@6.00	ME215961	1.07	1.08	0.93	0.94	1.04	0.95	1.00
PE 36:5; [M-H]-@5.90	ME216041	1.05	1.09	0.95	0.90	1.00	0.97	1.03
CL 80:9; [M-2H](2-)@6.01	ME215976	1.04	1.03	0.93	0.92	1.07	1.04	1.00
PG 38:4; [M-H]-@6.05	ME216075	1.04	1.01	0.92	0.95	1.08	0.99	1.05
PC 36:6; [M-Ac-H]-@5.40	ME216006	1.02	1.00	0.97	0.85	1.04	1.08	1.04
PI 40:6; [M-H]-@5.79	ME216087	1.03	0.98	0.97	0.90	1.02	1.08	1.03
PC 39:6; [M-Ac-H]-@6.75	ME216016	1.06	1.05	0.95	0.82	1.07	1.00	1.05
PC 42:10; [M-Ac-H]-@5.70	ME216022	1.06	1.06	0.94	0.83	1.04	1.03	1.03
CL 78:13; [M-2H](2-)@5.84	ME215966	1.03	1.08	0.95	0.85	1.00	1.03	1.06
PE 38:7; [M-H]-@5.83	ME216054	1.05	1.10	0.95	0.84	0.99	1.02	1.05
PC 40:8; [M-Ac-H]-@5.77	ME216021	1.06	1.04	0.96	0.85	1.00	1.06	1.01
CL 78:1; [M-2H](2-)@7.29	ME215965	1.06	1.04	0.96	0.89	0.97	1.01	1.05
PC 40:6; [M-Ac-H]-@6.68	ME216019	1.05	1.03	0.93	0.91	1.03	1.03	1.04
PC 34:4; [M-Ac-H]-@5.54	ME215995	1.06	1.05	0.94	0.87	1.03	1.01	1.04
PC 36:0; [M-Ac-H]-@7.79	ME216000	1.06	1.04	0.93	0.88	1.01	1.02	1.06
CL 72:5; [M-2H](2-)@6.24	ME215955	1.00	1.03	1.02	0.99	0.99	0.95	1.01
PC 38:7; [M-Ac-H]-@5.59	ME216014	1.05	1.06	1.00	0.92	0.99	0.95	0.97
PE 36:1; [M-H]-@7.40	ME216035	1.03	1.02	1.02	0.95	1.00	0.97	0.95
PC 31:1; [M-Ac-H]-@6.46	ME215985	0.97	1.02	0.99	1.03	1.02	1.04	0.98
PC 35:1; [M-Ac-H]-@7.01	ME215996	0.98	1.01	0.99	1.03	0.99	1.04	0.98
CerP 40:1; [M-H]-@7.70	ME215978	0.97	1.04	0.99	1.02	0.98	1.03	1.00
PE 36:0; [M-H]-@7.19	ME216034	0.99	1.03	0.98	1.04	0.96	1.04	0.99
PE 35:1; [M-H]-@7.10	ME216032	0.97	0.98	1.00	1.04	0.96	1.08	0.99
PG 35:3; [M-H]-@6.28	ME216069	0.97	0.97	1.02	1.01	1.00	1.06	0.99
PG 34:1; [M-H]-@5.84	ME216067	1.01	0.97	0.98	1.03	1.00	1.03	0.97
PA 34:0; [M-H]-@7.68	ME215982	1.00	0.97	1.00	1.02	0.99	1.04	0.98
PC 35:3; [M-Ac-H]-@6.10	ME215998	0.99	0.97	1.00	1.03	0.98	1.06	0.98
PE 36:2; [M-H]-@6.93	ME216038	1.02	1.01	1.01	1.00	0.99	0.99	0.94
PE 34:1; [M-H]-@6.82	ME216028	1.02	1.04	0.99	1.01	0.97	0.99	0.96
PE 34:2; [M-H]-@6.40	ME216029	1.02	1.02	1.01	1.01	0.97	0.98	0.95
PE 36:3; [M-H]-@6.50	ME216039	1.02	1.02	1.00	1.01	0.98	0.99	0.96
PS 38:4; [M-H]-@5.96	ME216088	1.05	1.02	0.97	0.97	0.97	1.02	0.99
CL 74:3; [M-2H](2-)@6.22	ME215958	1.03	1.01	1.00	0.97	0.99	1.00	0.97
plasmenyl-PE 38:1; [M-H]-@8.18	ME216107	1.04	0.99	0.99	0.98	0.99	1.02	0.98
PE 36:2; [M-H]-@6.25	ME216037	1.03	1.01	0.99	0.99	0.98	1.00	0.98
PC 34:2; [M-Ac-H]-@6.23	ME215993	1.03	1.01	0.99	0.98	0.98	1.02	0.98
plasmenyl-PE 38:2; [M-H]-@7.84	ME216108	1.02	1.01	0.99	0.98	0.99	1.02	0.99
PE 38:4; [M-H]-@6.18	ME216049	1.02	1.01	0.98	0.99	0.98	1.04	0.99
PC 33:2; [M-Ac-H]-@5.95	ME215990	1.02	1.01	0.99	1.00	0.99	1.03	0.95
PC 36:3; [M-Ac-H]-@6.41	ME216003	1.02	1.00	0.99	1.00	0.99	1.03	0.97
PE 40:5; [M-H]-@7.06	ME216058	1.02	1.01	0.98	1.00	0.98	0.99	1.01
CL 76:5; [M-2H](2-)@6.89	ME215964	1.01	1.03	0.98	1.02	0.98	1.00	0.99
lysoPE 18:2; [M-H]-@1.31	ME216094	1.01	1.02	0.99	1.01	0.97	1.01	0.98
PC 32:0; [M-Ac-H]-@6.59	ME215986	1.01	0.98	1.00	1.01	0.99	1.02	0.99
PG 34:2; [M-H]-@5.37	ME216068	1.01	0.99	1.00	1.00	0.97	1.02	1.01
plasmenyl-PE 34:1; [M-H]-@7.13	ME216101	1.02	0.99	0.99	0.99	1.01	1.00	1.00
PC 36:2; [M-Ac-H]-@6.87	ME216002	1.02	1.00	0.99	0.98	1.00	1.01	1.00
plasmenyl-PE 38:5; [M-H]-@6.90	ME216111	1.01	1.00	0.99	0.98	1.00	1.02	1.01
plasmenyl-PE 34:2; [M-H]-@6.69	ME216102	1.01	0.99	1.00	1.00	0.99	1.00	0.97
PC 37:2; [M-Ac-H]-@7.21	ME216007	0.99	0.99	1.00	1.02	1.00	1.00	0.99
PI 37:4; [M-H]-@5.54	ME216081	1.00	1.00	1.00	1.00	1.00	1.00	1.00
PC 34:0; [M-Ac-H]-@7.21	ME215991	1.00	1.00	1.00	1.00	1.00	1.00	1.00
PE 34:0; [M-H]-@7.23	ME216026	1.00	1.00	1.00	1.00	1.00	1.00	1.00
PC 39:4; [M-Ac-H]-@7.18	ME216015	1.00	1.01	1.01	1.01	1.05	0.95	0.98
PC 35:2; [M-Ac-H]-@6.53	ME215997	1.01	0.99	0.98	1.04	1.03	0.98	1.00
PE 39:2; [M-H]-@6.86	ME216055	1.00	1.01	0.97	1.03	1.02	1.00	0.99
CL 74:5; [M-2H](2-)@5.74	ME215959	1.01	1.06	1.00	1.02	0.94	1.05	0.91
PE 35:2; [M-H]-@6.68	ME216033	1.04	1.05	1.00	0.99	0.94	1.01	0.94
PE 37:4; [M-H]-@6.65	ME216042	1.04	1.05	1.00	0.98	0.96	0.99	0.96
PE 38:5; [M-H]-@5.75	ME216052	1.04	1.05	0.99	0.96	0.95	0.99	0.97
PI 38:5; [M-H]-@5.35	ME216084	1.04	1.05	1.00	0.96	0.94	1.01	0.97
PI 36:2; [M-H]-@5.84	ME216078	1.02	0.99	1.01	1.00	0.96	1.04	0.95
PA 36:3; [M-H]-@6.23	ME215983	1.01	1.01	1.02	1.00	0.94	1.04	0.95
PI 36:3; [M-H]-@5.37	ME216079	1.00	1.00	1.02	1.01	0.95	1.03	0.96
PC 38:2; [M-Ac-H]-@7.45	ME216009	1.02	1.01	1.01	0.99	0.90	1.05	0.98
CL 78:9; [M-2H](2-)@5.74	ME215973	1.05	1.03	0.98	0.99	0.92	1.03	0.98
PI 36:4; [M-H]-@5.21	ME216080	1.03	1.03	1.00	0.99	0.93	1.03	0.98
PG 38:5; [M-H]-@5.26	ME216076	1.04	0.99	0.93	0.99	1.02	1.07	0.99
CL 82:15; [M-2H](2-)@5.98	ME215977	1.07	1.02	0.95	0.95	0.93	1.03	1.03
PE 42:10; [M-H]-@5.81	ME216063	1.06	1.02	0.97	0.93	0.93	1.01	1.03
PE 32:0; [M-H]-@6.75	ME216024	1.06	0.99	0.97	1.00	0.91	1.02	1.02
PE 38:3; [M-H]-@6.42	ME216046	1.03	0.98	0.97	0.98	0.96	1.04	1.03
PC 37:4; [M-Ac-H]-@6.54	ME216008	1.00	1.00	0.96	0.98	1.05	1.02	1.03
PG 36:3; [M-H]-@5.55	ME216073	1.00	1.00	0.94	1.00	1.03	1.03	1.06
PC 33:1; [M-Ac-H]-@6.41	ME215989	1.03	1.03	0.98	0.92	1.05	0.99	0.99
PE 37:5; [M-H]-@6.16	ME216043	1.00	1.02	0.99	0.95	1.06	0.99	1.00
CL 78:4; [M-2H](2-)@6.45	ME215968	0.98	1.02	1.02	0.97	1.02	1.00	0.99
PC 42:9; [M-Ac-H]-@6.11	ME216023	0.99	1.05	0.99	0.97	1.03	1.03	0.98
PE 40:5; [M-H]-@6.33	ME216059	1.01	1.02	0.97	0.97	1.03	1.05	0.97
plasmenyl-PE 34:0; [M-H]-@7.17	ME216100	1.03	1.04	0.97	0.93	0.97	1.06	0.98
PE 38:1; [M-H]-@7.31	ME216044	1.06	1.02	0.98	0.92	0.98	0.96	1.03
plasmenyl-PE 36:5; [M-H]-@6.27	ME216106	1.05	1.06	0.93	0.93	0.98	1.00	1.06
CL 78:7; [M-2H](2-)@6.22	ME215971	1.03	1.04	0.94	0.93	0.99	1.03	1.06
lysoPE 20:3; [M-H]-@1.60	ME216095	1.03	1.04	0.95	0.95	1.00	1.01	1.05
PC 40:5; [M-Ac-H]-@7.05	ME216018	1.03	1.03	0.95	0.93	1.00	1.00	1.07
PE 40:6; [M-H]-@6.10	ME216060	1.04	1.02	0.95	0.93	0.99	1.05	1.02
plasmenyl-PE 42:6; [M-H]-@7.70	ME216118	1.04	1.02	0.96	0.92	0.98	1.05	1.03
lysoPE 22:6; [M-H]-@1.28	ME216099	1.03	1.01	0.96	0.91	1.01	1.04	1.04
PC 36:1; [M-Ac-H]-@7.30	ME216001	1.04	1.01	0.97	0.92	1.01	1.02	1.03
PC 40:7; [M-Ac-H]-@6.22	ME216020	1.04	1.03	0.96	0.91	1.01	1.02	1.04
PG 34:0; [M-H]-@6.27	ME216066	1.05	1.05	0.96	0.93	0.98	1.01	1.02
lysoPE 16:1; [M-H]-@1.22	ME216091	1.04	1.03	0.94	0.96	0.99	1.03	1.02
PG 36:1; [M-H]-@6.45	ME216071	1.04	1.03	0.94	0.94	1.01	1.02	1.02
CL 76:1; [M-2H](2-)@6.68	ME215962	1.01	0.97	1.00	0.96	1.02	1.01	1.03
PE 34:2; [M-H]-@4.87	ME216030	1.04	1.00	1.00	0.94	0.97	1.04	0.98
PC 34:3; [M-Ac-H]-@5.78	ME215994	1.04	1.03	0.99	0.94	0.97	0.99	1.01
PI 38:3; [M-H]-@6.06	ME216082	1.04	1.02	0.99	0.92	0.96	1.02	1.01
PG 36:4; [M-H]-@5.43	ME216074	1.04	1.01	0.99	0.94	0.99	1.01	1.01
PI 38:4; [M-H]-@5.82	ME216083	1.04	1.01	0.99	0.93	0.98	1.03	1.00
PA 26:3; [M-H]-@1.50	ME215979	1.00	1.02	0.99	0.98	1.01	0.98	1.03
CL 78:3; [M-2H](2-)@6.76	ME215967	1.00	1.03	0.98	0.97	0.99	1.00	1.04
PE 38:2; [M-H]-@6.84	ME216045	1.02	1.03	0.98	0.96	0.97	1.00	1.04
PE 36:1; [M-H]-@6.68	ME216036	1.03	1.00	0.99	0.96	1.02	0.98	0.99
PC 32:1; [M-Ac-H]-@6.07	ME215987	1.04	1.01	0.97	0.97	0.99	1.00	1.00
PE 38:4; [M-H]-@6.94	ME216048	1.02	1.01	0.98	0.97	1.01	1.00	1.00
PC 32:2; [M-Ac-H]-@5.60	ME215988	1.03	1.01	0.98	0.96	1.01	1.00	1.00
PC 34:1; [M-Ac-H]-@6.67	ME215992	1.03	1.01	0.98	0.96	1.02	1.00	1.01
PE 38:5; [M-H]-@6.50	ME216051	1.03	1.03	0.97	0.96	1.00	1.00	1.00
PE 38:6; [M-H]-@6.11	ME216053	1.03	1.02	0.98	0.96	1.00	0.99	1.02
PE 40:7; [M-H]-@6.32	ME216061	1.03	1.02	0.97	0.96	1.01	1.00	1.02
PC 36:5; [M-Ac-H]-@5.69	ME216005	1.03	1.03	0.97	0.93	1.01	1.01	1.02
PC 38:5; [M-Ac-H]-@6.41	ME216012	1.03	1.03	0.97	0.94	1.00	1.01	1.01
lysoPE 18:1; [M-H]-@1.80	ME216093	1.02	1.04	0.97	0.96	0.99	0.99	1.02
lysoPE 22:5; [M-H]-@1.60	ME216098	1.03	1.03	0.98	0.96	0.98	0.99	1.02
lysoPE 16:0; [M-H]-@1.65	ME216090	1.02	1.02	0.98	0.96	0.99	1.01	1.01
PE 38:3; [M-H]-@7.18	ME216047	1.03	1.03	0.98	0.95	0.98	1.01	1.02
PE 40:8; [M-H]-@5.96	ME216062	1.03	1.03	0.97	0.95	0.99	1.01	1.02
PA 28:4; [M-H]-@1.82	ME215980	1.03	1.04	0.98	0.93	1.01	0.98	1.02
CL 74:7; [M-2H](2-)@6.06	ME215960	1.03	1.05	0.97	0.97	1.01	0.98	1.00
PE 36:4; [M-H]-@6.24	ME216040	1.03	1.05	0.97	0.96	1.01	0.98	1.00
PC 30:0; [M-Ac-H]-@5.94	ME215984	1.03	1.00	0.96	0.97	0.99	1.02	1.05
PC 40:4; [M-Ac-H]-@7.30	ME216017	1.03	1.00	0.97	0.95	1.00	1.00	1.04
PE 38:5; [M-H]-@4.99	ME216050	1.04	1.00	0.95	0.96	1.01	1.01	1.04
PC 38:4; [M-Ac-H]-@6.74	ME216011	1.03	1.00	0.96	0.94	1.03	1.01	1.04
PE 40:4; [M-H]-@6.84	ME216056	1.02	0.98	0.96	0.96	1.04	1.00	1.05
CL 78:6; [M-2H](2-)@5.95	ME215970	1.03	0.99	0.96	0.98	1.01	1.02	1.02
PC 35:4; [M-Ac-H]-@5.91	ME215999	1.02	1.00	0.97	0.97	1.03	1.02	1.02
PG 36:2; [M-H]-@5.91	ME216072	1.02	1.00	0.96	0.97	1.03	1.02	1.01
lysoPE 20:4; [M-H]-@1.32	ME216096	1.02	1.01	0.97	0.97	1.01	1.01	1.02
PC 36:4; [M-Ac-H]-@6.08	ME216004	1.03	1.01	0.97	0.96	1.02	1.02	1.01
CL 78:5; [M-2H](2-)@6.42	ME215969	1.02	1.00	0.98	0.96	1.03	1.02	0.99
PC 38:3; [M-Ac-H]-@7.08	ME216010	1.03	0.99	0.97	0.97	1.02	1.04	1.00
plasmenyl-PE 38:4; [M-H]-@7.20	ME216110	1.03	0.98	0.99	0.93	1.00	1.03	1.02
plasmenyl-PE 40:4; [M-H]-@7.70	ME216113	1.03	0.99	0.98	0.96	0.99	1.03	1.02
CL 74:1; [M-2H](2-)@5.98	ME215956	1.02	1.00	0.99	0.94	1.00	1.03	1.03
plasmenyl-PE 38:3; [M-H]-@7.48	ME216109	1.03	1.00	0.98	0.94	0.99	1.03	1.02
plasmenyl-PE 40:5; [M-H]-@7.40	ME216114	1.04	1.01	0.97	0.94	0.98	1.04	1.01
plasmenyl-PE 38:6; [M-H]-@6.51	ME216112	1.04	1.00	0.97	0.95	1.00	1.04	1.00
plasmenyl-PE 42:5; [M-H]-@7.81	ME216117	1.04	1.00	0.97	0.94	1.00	1.05	1.00
lysoPE 18:0; [M-H]-@2.42	ME216092	1.04	1.01	0.97	0.94	0.99	1.02	1.03
PC 38:6; [M-Ac-H]-@5.98	ME216013	1.03	1.01	0.96	0.96	1.00	1.03	1.02
plasmenyl-PE 40:6; [M-H]-@7.07	ME216115	1.04	1.00	0.96	0.96	1.01	1.03	1.01
plasmenyl-PE 36:2; [M-H]-@7.30	ME216104	1.04	1.00	0.97	0.96	1.00	1.01	1.01
plasmenyl-PE 36:4; [M-H]-@6.63	ME216105	1.03	1.00	0.98	0.95	1.00	1.02	1.01
CL 74:1; [M-2H](2-)@6.76	ME215957	1.04	0.99	1.01	1.00	0.97	1.00	0.93
plasmenyl-PE 36:1; [M-H]-@7.69	ME216103	1.05	0.95	1.02	1.00	0.96	1.00	0.95
CL 76:3; [M-2H](2-)@6.23	ME215963	1.03	1.01	1.04	1.01	0.93	1.00	0.91
PI 34:2; [M-H]-@5.22	ME216077	1.03	0.97	1.03	1.05	0.95	1.02	0.90
PI 40:3; [M-H]-@5.27	ME216085	1.01	1.04	1.04	1.01	0.88	0.96	1.00
PE 34:0; [M-H]-@6.58	ME216027	0.99	1.01	1.03	1.06	0.94	0.96	0.98
PG 32:0; [M-H]-@5.76	ME216065	1.01	1.05	1.00	1.03	0.93	0.99	0.98

Factors:

F1	Age (months):10.1 \| Diet:Mediterranean
F2	Age (months):10.3 \| Diet:Western
F3	Age (months):10.4 \| Diet:Control
F4	Age (months):10.4 \| Diet:Mediterranean
F5	Age (months):10.4 \| Diet:Western
F6	Age (months):10.5 \| Diet:Control
F7	Age (months):10.5 \| Diet:Western

Data matrix